Evidence map›Paper›PMID 39273422›Full record

ArticleInternational journal of molecular sciences2024

Spatiotemporal Dysregulation of Neuron-Glia Related Genes and Pro-/Anti-Inflammatory miRNAs in the

Marta Ianni, Miriam Corraliza-Gomez, Tiago Costa-Coelho, Mafalda Ferreira-Manso, Sara Inteiro-Oliveira, Nuno Alemãn-Serrano, Ana M Sebastião, Gonçalo Garcia, Maria José Diógenes, Dora Brites

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marta IanniInstituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0009-0008-0241-967X
Miriam Corraliza-GomezInstituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0000-0002-1417-2757
Tiago Costa-CoelhoInstituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, 1649-003 Lisboa, Portugal.
Mafalda Ferreira-MansoInstituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0000-0001-5074-8154
Sara Inteiro-OliveiraInstituto de Farmacologia e Neurociências, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal.
Nuno Alemãn-SerranoInstituto de Farmacologia e Neurociências, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal.ORCID 0000-0003-2100-1240
Ana M SebastiãoInstituto de Farmacologia e Neurociências, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal.
Gonçalo GarciaInstituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0000-0001-5526-5362
Maria José DiógenesInstituto de Farmacologia e Neurociências, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisboa, Portugal.
Dora BritesInstituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia da Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0000-0002-3024-9777

Funding

European Union, Erasmus+ 2022/23Fundação para a Ciência e Tecnologia 2023.01388.BDFundação para a Ciência e Tecnologia 5/2022/PTDC/MED-NEU/2382/2021Fundação para a Ciência e Tecnologia FCT-PTDC/MED-NEU/2382/2021Fundação para a Ciência e Tecnologia LISBOA-01-0145-FEDER-031395Fundação para a Ciência e Tecnologia UIDB/04138/2020Fundação para a Ciência e Tecnologia UIDP/04138/2020Fundación "Margarita Salas" 2022/23La Caixa Foundation-Luzón Foundation HR21-00931NextGenerationEU PRR-02/C05-i01/2022SCML MB35-2021
6 · The paper itself

Abstract

Alzheimer's disease (AD), the leading cause of dementia, is a multifactorial disease influenced by aging, genetics, and environmental factors. miRNAs are crucial regulators of gene expression and play significant roles in AD onset and progression. This exploratory study analyzed the expression levels of 28 genes and 5 miRNAs (miR-124-3p, miR-125b-5p, miR-21-5p, miR-146a-5p, and miR-155-5p) related to AD pathology and neuroimmune responses using RT-qPCR. Analyses were conducted in the prefrontal cortex (PFC) and the hippocampus (HPC) of the

Indexed as

Alzheimer DiseaseDisease Models, AnimalHippocampusMicroRNAsNeurogliaNeuronsAnimalsGene Expression RegulationGlial Fibrillary Acidic ProteinMaleMembrane GlycoproteinsMiceMice, TransgenicPrefrontal CortexReceptors, ImmunologicGlial Fibrillary Acidic Proteinglial fibrillary astrocytic protein, mouseMembrane GlycoproteinsMicroRNAsMirn125 microRNA, mouseMirn146 microRNA, mouseMirn155 microRNA, mouseMIRN21 microRNA, mouseReceptors, ImmunologicTrem2 protein, mouse5xFAD mouse modelAlzheimer’s diseasehippocampusmicroRNAsneurodegenerationneuroimmune genesneuroinflammationprefrontal cortex

Identifiers

PMID39273422
PMCPMC11394861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.